Workshop on Immune System Engineering for Targeted Tolerance in Type 1 Diabetes (T1D)
Type 1 diabetes results in part from the autoimmune destruction of the insulin-producing pancreatic beta cells. It may be possible to change the course of the disease by interfering with autoimmune pathogenesis and re-establishing tolerance. For example, immune responses may be de-activated specifically and safely through the development of tolerizing vaccines, or through the direct manipulation of regulatory and other cells for applications in cell therapy.
In this Workshop, scientists from diverse fields (bioengineering, microbiomics, cancer immunology, etc.) will come together with diabetes experts to discuss how new knowledge, tools and technologies may be applied to reverse autoimmunity.
Examples of topics for discussion include:
- Development of safe tolerizing adjuvants or delivery systems
- The development of materials that deliver specific antigens in ways that direct the immune response towards active tolerance.
- Understanding of anti-inflammatory or autoimmune mechanisms that are specific and can be manipulated or targeted.
- Engineer immune system cells for use as highly specific therapeutics
- Re-directing effector immune cells to eliminate pathogenic cell types.
- Re-directing or strengthening immune regulatory cells to dampen the overactive immune system at sites of autoimmune damage.
October 15, 2017
This meeting is being held in conjunction with the Autoantigens Discovery and Characterization in Type 1 Diabetes workshop.